12 February 2026 : Review article
Mechanism, Dose, and Administration of Dexmedetomidine in Managing Visceral Pain Associated With Surgery: A Narrative Review
Ruonan Tian EF 1, Zongming Jiang AEFG 1,2*, Han Zhou F 1, Yunzhi Wang F 2DOI: 10.12659/MSM.950564
Med Sci Monit 2026; 32:e950564
Table 2 Clinical evidence of DEX alleviates visceral pain.
| Year/Refs | Type of operation/Experimental subject | DEX administration timing | Combination medication | Administration routes | Upward indicators | Reduction indicators | Results |
|---|---|---|---|---|---|---|---|
| 2014/[]78 | Colorectal surgery | Intraoperative | Adjuvant drug | IV | NR | Resting pain scores | Reduction pain scores at rest |
| 2016/[]115 | Laparoscopic surgery | At the end of surgery | DEX with bupivacaine versus bupivacaine alone | Intraperitoneal instillation | Duration of analgesia | VAS | Prolongs the duration of postoperative analgesia |
| 2017/[]83 | Abdominal hysterectomy | Intraoperative | Combined with lidocaine | IV | Analgesic and opioid-sparing effects | VAS after surgery; fentanyl doses | Significantly improved postoperative pain and enhanced recovery of bowel function. |
| 2017/[]105 | Cesarean surgery | Preoperative | Low dose of DEX as an adjuvant to bupivacaine | Spinal anesthesia | NR | Plasma IL-6 and cortisol levels | DEX(3 μg) provides better somato-visceral sensory block characteristics and postoperative analgesia |
| 2018/[]81 | Cesarean delivery | After delivery | Combined with sufentanil | IV | Satisfaction degree | VAS; rescue analgesia | Enhance the analgesic effects; improve the recovery of intestinal functions |
| 2018/[]82 | Abdominal operation | After abdominal operation | Combined with sufentanil | Patient-controlled analgesia | Satisfaction degree of patient | VAS; sufentanil consumption. | Reduce sufentanil consumption, decrease VAS, lower the rate of nausea and vomiting, improve patient satisfaction |
| 2018/[]91 | Laparoscopic assisted operations on stomach and intestines | Postoperative analgesic | Different doses of DEX in combination with oxycodone | IV | Patients’ satisfaction ratings | VAS at 4, 6, and 12 h after surgery | DEX combined with oxycodone can improve sleep quality and provide good visceral analgesia |
| 2019/[]61 | Videolaparoscopic cholecystectomy | Intraoperative | an adjuvant drug | IV | NR | IL-6; VAS | Good analgesia; faster postoperative recovery |
| 2021/[]28 | Thoracotomy | Intraoperative | An adjuvant drug | IV | NR | TLR4 and NF-κB expressions; TNF-α; IL-1β; epinephrine and norepinephrine | Reduce the stress response and postoperative pain intensity |
| 2021/[]99 | Laparoscopic cholecystectomy | Before induction | Different doses of DEX | IV | NR | VAS; the dosage of postoperative analgesic | IV infusion of 0.6 μg/kg DEX can maintain hemodynamic stability, relieve postoperative pain |
| 2021/[]101 | Laparoscopic hysterectomy | 10 min before the induction of anesthesia-30 min before the end of the operation | Combined with lidocaine | IV | NR | IL-1β; IL-6; TNF-α; intraoperative consumption of remifentanil and propofol; post-operative VAS at rest | The combination of lidocaine and DEX significantly alleviated the inflammatory responses, decreased postoperative pain |
| 2021/[]104 | Thoracoscopic surgery | Postoperative | Combined with sufentanil and dezocine | Patient-controlled analgesia | Patients’ overall satisfaction degree | Postoperative pain scores; the incidence of nausea and vomiting | Enhanced patient satisfaction, improved postoperative analgesia, and reduced postoperative nausea and vomiting |
| 2021/[]120 | Laparoscopic cholecystectomy | Postoperative | DEX versus clonidine as adjuvants to local anesthetic | Intraperitoneal instillation | Duration of analgesia | NR | The addition of DEX to bupivacaine for intraperitoneal injection provides a longer period of postoperative analgesia |
| 2022/[]77 | Gastro-intestinal surgery | Intraoperative | An adjuvant drug | IV | a7nAChR level | TNF-α; hospital stay; D-lactate level | DEX maintained intestinal barrier integrity |
| 2022/[]79 | Colorectal surgery | Intraoperative | Bolus plus maintenance dose | IV | IL-10 | IL-6; TNF-α; cyclo-oxygenase-2; inducible nitric oxide synthase; lipopolysaccharide | DEX used with an extra loading dose enhanced the recovery of gastrointestinal function |
| 2022/[]80 | Laparoscopic hysteromyomectomy | Intraoperative | An adjuvant drug | IV | NR | First flatus, first oral feeding, and first defecation; postoperative pain scores. | Improve gastrointestinal function recovery after laparoscopic hysteromyomectomy |
| 2022/[]118 | Abdominal laparoscopic cancer Surgeries | Before start of surgery or after completion of surgery | DEX versus tramadol as adjuvants to local anesthetic (bupivacaine) | Intraperitoneal instillation | NR | Opioid consumption | DEX as an adjuvant drug to bupivacaine resulted in significant reduction in perioperative fentanyl consumption |
| 2023/[]41 | Cesarean section | preoperative | Combined with ropivacaine | Epidural anesthesia | Sedation scores | Visceral traction reaction | Alleviate visceral traction reaction |
| 2023/[]60 | Video-laparoscopic cholecystectomy | Intraoperative | An adjuvant drug | IV | NR | IL-6 | Lower pain and opioid consumption in the first postoperative hour |
| 2023/[]94 | Major non-cardiac surgery | Initiated from the end of surgery | Supplementing IV analgesia with mini-dose DEX | IV | Percentage of N2 sleep | Percentage of N1 sleep | Improve sleep structure without increasing sedation in older patients recovering from major surgery |
| 2023/[]97 | Emergency trauma surgery | Intraoperative | An adjuvant drug | IV | Sleep quality | Beck anxiety inventory for anxiety score | Lower post-traumatic stress disorder incidence; improved sleep quality |
| 2023/[]98 | Epidural labor analgesia | Immediately after labor analgesia | Different doses of DEX | IV | NR | VAS | Low-dose DEX is highly safe and effectively relieves the pain of puerperae and shorten the labor process |
| 2023/[]102 | Cesarean delivery | Postoperative | Administration of DEX with nalbuphine versus sufentanil | Patient-controlled analgesia | Patient’s satisfaction | Adverse reactions | The combination yields superior efficacy in alleviating postoperative visceral pain and fewer side effects |
| 2023/[]109 | Thoracic surgery | Preoperative | DEX versus dexamethasone as adjuvants to local anesthetic (ropivacaine) | Epidural anesthesia | NR | VAS | DEX was more efficient in lowering pain and analgesia requirements 24 h after the surgery |
| 2023/[]119 | Laparoscopic surgeries | Postoperative | DEX versus ketamine as adjuvants to local anesthetic (ropivacaine) | Intraperitoneal instillation | NR | VAS | Intraperitoneal instillation of local anesthetics with DEX is more effective for postoperative analgesia |
| 2024/[]40 | Cesarean section | After umbilical cord clamping | Combined with esketamine | Spinal-epidural anesthesia | NR | VAS | Alleviate visceral traction pain |
| 2024/[]100 | Laparoscopic cholecystectomy | Premedication | Low-dose DEX as an adjuvant drug | IV | Incidence of bradycardia | Anesthetic consumption; postoperative VAS | Effectively attenuate intraoperative stress response and postoperative pain |
| 2024/[]116 | Malignancy-associated refractory abdominal pain | Premedication | An adjuvant drug | Splanchnic nerve neurolysis | NR | VAS, morphine requirement | Improves pain results from refractory cancer related pain |
| 2024/[]121 | Laparoscopic hysterectomy | Before the end of pneumoperitoneum | DEX with ropivacaine versus ropivacaine alone | Intraperitoneal spraying | 40-item questionnaire | VAS; incidences of dizziness, nausea, and vomiting | Improves the quality of recovery, postoperative analgesia after general anesthesia |
| 2024/[]124 | Cesarean sections | Preoperative | DEX with ropivacaine versus ropivacaine alone | Transversus abdominis plane block | Duration of analgesia; patient’s satisfaction | VAS at 12 h and 18 h after surgery | Significantly increases the duration of postoperative analgesia |
| DEX – dexmedetomidine; NR – no report; Refs – references; VAS – visual analogue scale; IV – intravenous injection; IL-6 – interleukin 6; IL-10 – interleukin 10; IL-1β – interleukin-1β; TLR – toll-like receptor; NF-κB – nuclear factor-κB. | |||||||






